Catalog Home Page

Patents associated with high-cost drugs in Australia

Derrick, G.E., Christie, A.F., Dent, C., McIntyre, P., Wilson, L. and Studdert, D.M. (2013) Patents associated with high-cost drugs in Australia. PLoS ONE, 8 (4). e60812.

PDF - Published Version
Available under License Creative Commons Attribution.

Download (469kB) | Preview
Link to Open Access version:
*No subscription required


Australia, like most countries, faces high and rapidly-rising drug costs. There are longstanding concerns about pharmaceutical companies inappropriately extending their monopoly position by "evergreening" blockbuster drugs, through misuse of the patent system. There is, however, very little empirical information about this behaviour. We fill the gap by analysing all of the patents associated with 15 of the costliest drugs in Australia over the last 20 years. Specifically, we search the patent register to identify all the granted patents that cover the active pharmaceutical ingredient of the high-cost drugs. Then, we classify the patents by type, and identify their owners. We find a mean of 49 patents associated with each drug. Three-quarters of these patents are owned by companies other than the drug's originator. Surprisingly, the majority of all patents are owned by companies that do not have a record of developing top-selling drugs. Our findings show that a multitude of players seek monopoly control over innovations to blockbuster drugs. Consequently, attempts to control drug costs by mitigating misuse of the patent system are likely to miss the mark if they focus only on the patenting activities of originators

Publication Type: Journal Article
Publisher: Public Library of Science
Copyright: © 2013 Christie et al.
Item Control Page Item Control Page


Downloads per month over past year